Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Cerus Corporation CERS | Baker Bros. Advisors LP | 19,497,203 10.800% | 395,327 (+2.07%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | HOOKIPA Pharma Inc. HOOK | Baker Bros. Advisors LP | 814,899 9.990% | 467,345 (+134.47%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 5,838,853 6.900% | 651,772 (+12.57%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Monte Rosa Therapeutics, Inc. GLUE | Baker Bros. Advisors LP | 4,916,095 9.800% | 4,916,095 (New Position) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Nurix Therapeutics, Inc. NRIX | Baker Bros. Advisors LP | 4,952,452 9.990% | 150,498 (+3.13%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | OPTHEA LTD SPONSORED ADR OPTEY | Baker Bros. Advisors LP | 28,100,345 4.200% | -3,527,499 (-11.15%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Rhythm Pharmaceuticals, Inc. RYTM | Baker Bros. Advisors LP | 6,398,365 10.800% | 43,757 (+0.69%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Sagimet Biosciences Inc. SGMT | Baker Bros. Advisors LP | 1,456,518 6.800% | 1,456,518 (New Position) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | Baker Bros. Advisors LP | 0 0.000% | -4,954,855 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Athira Pharma, Inc. ATHA | Baker Bros. Advisors LP | 315,381 8.300% | 315,381 (New Position) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX | Baker Bros. Advisors LP | 10,204,089 4.980% | -8,980,705 (-46.81%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | Biomea Fusion, Inc. BMEA | Baker Bros. Advisors LP | 2,108,949 5.900% | 4,390 (+0.21%) | Filing History |
| 2024-02-14 4:21 pm Purchase | 2023-12-31 | 13G | KALA BIO, Inc. KALA | Baker Bros. Advisors LP | 269,213 9.990% | 88,300 (+48.81%) | Filing History |
| 2024-02-12 4:10 pm Purchase | 2024-01-31 | 13G | Bicycle Therapeutics plc BCYC | Baker Bros. Advisors LP | 4,823,598 12.800% | 4,823,598 (New Position) | Filing History |
| 2024-02-01 5:25 pm Sale | 2024-01-30 | 13D | Immunocore Holdings plc IMCR | Baker Bros. Advisors LP | 2,452,871 4.990% | -2,232,819 (-47.65%) | Filing History |
| 2024-01-10 4:58 pm Purchase | 2023-12-31 | 13G | Sera Prognostics, Inc. SERA | Baker Bros. Advisors LP | 5,434,399 17.900% | 5,434,399 (New Position) | Filing History |
| 2024-01-10 4:57 pm Purchase | 2023-12-31 | 13G | Replimune Group, Inc. REPL | Baker Bros. Advisors LP | 9,545,336 16.200% | 3,777,109 (+65.48%) | Filing History |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Atreca, Inc. BCEL | Baker Bros. Advisors LP | 7,677,982 19.990% | 4,145,222 (+117.34%) | Filing History |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Baker Bros. Advisors LP | 5,995,928 10.800% | 3,116,103 (+108.20%) | Filing History |
| 2023-12-20 5:24 pm Purchase | 2023-12-18 | 13D | Neurogene Inc. NGNE | Baker Bros. Advisors LP | 649,685 4.990% | 649,685 (New Position) | Filing History |